Pediatric Myelodysplastic Syndrome: Cytomorphological Correlation with Outcome from a Single Tertiary Institution in Oman
European Journal of Clinical and Biomedical Sciences
Volume 3, Issue 6, December 2017, Pages: 109-114
Received: Oct. 15, 2017; Accepted: Oct. 27, 2017; Published: Nov. 20, 2017
Views 1690      Downloads 147
Naglaa Fawaz, Department of Hematology, Sultan Qaboos University Hospital, Muscat, Oman; Department of Haematopathology, Suez Canal University, Ismailia, Egypt
Abdulhakim Al Rawas, Department of Child Health, Sultan Qaboos University Hospital, Muscat, Oman
Muhammad El Shinawi, Department of Child Health, Sultan Qaboos University Hospital, Muscat, Oman
Mathew Zachariah, Department of Child Health, Sultan Qaboos University Hospital, Muscat, Oman
Yasser Wali, Department of Child Health, Sultan Qaboos University Hospital, Muscat, Oman
Salam Alkindi, College of Medicine & Health Sciences, Sultan Qaboos University, Muscat, Oman
Anil Pathare, Department of Hematology, Sultan Qaboos University Hospital, Muscat, Oman
Article Tools
Follow on us
Pediatric MDS is currently classified into three distinct groups namely MDS, Juvenile myelomonocytic leukemia (JMML) and Down Syndrome-associated leukemias (DSAL). The aim of this study was to evaluate pediatric MDS patients using the WHO 2008 morphological classification with the clinical outcome. In this retrospective single centre study, 19 pediatric MDS patients (median age 6 years; range 3 months – 16 years) were analyzed for their initial presentation, type of progression, leukemic transformation and overall survival as well as MDS related cytogenetic abnormalities. The median follow-up was 26.5 months. The most common single presentation of childhood MDS was RCC (26%). Leukemic transformation was seen in almost half of this cohort but was completely restricted to the DSAL and RAEB-T subgroups only. The median survival in the MDS group was 50 months, whereas for the entire cohort it was 35 months. RCC cohort showed the best survival with the median of 53.75 months, whereas the Down-related disease cohort showed the worst survival estimates with a median of only 11.25 months. Multivariate analysis showed that gender, platelet count, HbF, bone marrow cellularity, bone marrow blast percentage contributed significantly to the prognosis and survival. The study shows that cytogenetics, including monosomy 7 did not influence the outcome or the overall survival of childhood MDS. We identified that thrombocytopenia and BM blasts >5% were associated with a poor survival in this childhood MDS cohort.
Pediatric, MDS, Cytopenia, Myelodysplasia, Monosomy 7, Down’s Syndrome
To cite this article
Naglaa Fawaz, Abdulhakim Al Rawas, Muhammad El Shinawi, Mathew Zachariah, Yasser Wali, Salam Alkindi, Anil Pathare, Pediatric Myelodysplastic Syndrome: Cytomorphological Correlation with Outcome from a Single Tertiary Institution in Oman, European Journal of Clinical and Biomedical Sciences. Vol. 3, No. 6, 2017, pp. 109-114. doi: 10.11648/j.ejcbs.20170306.12
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License ( which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Williamson PJ, Kruger AR, Reynolds PJ, Hamblin TJ, Oscier DG. Establishing the incidence of myelodysplastic syndrome. Br J Haematol,. 1994; 87:743-745.
Alter BP, Giri N, Savage SA, et al. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol. 2010;150:179-188.
Glaubach T, Robinson LJ, Corey SJ. Pediatric myelodysplastic syndromes: they do exist! J Pediatr Hematol Oncol. 2014; 36:1-7.
Hasle H, Wadsworth LD, Massing BG, et al. A population based study of childhood myelodysplastic syndrome in British Columbia, Canada. Br J Haematol. 1999;106:1027–1032.
Passmore SJ, Chessells JM, Kempski H, et al. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: a population-based study of incidence and survival. Br J Haematol. 2003;121:758–767.
Bader-Meunier B, Mielot F, Tchernia G, et al. Myelodysplastic syndromes in childhood: report of 49 patients from a French multicenter study. Br J Haematol 1996; 92: 344–50.
Sasaki H, Manabe A, Kojima S, et al. Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan. Leukemia. 2001;15:1713–1720.
Luna-Fineman S, Shannon KM, Atwater SK, et al. Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients. Blood. 1999;93:459–466.
Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982; 51:189-199
Jaffe JS, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues. 3rd ed. Lyon, France: IARC Press; 2001.
Hasle H, Niemeyer CM, Chessells JM, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 2003; 17:277-282.
Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937-951.
Mitelman F, editor. ISCN (1995): An international system for human cytogenetic nomenclature. Basel: S Karger; 1995.
Niemeyer CM, Baumann I. Myelodysplastic syndrome in children and adolescents. Semin Hematol. 2008;45:60–70.
Pitman SD, Victorio A, Rowsell E, et al. 5qsyndrome in a child with slowly progressive pancytopenia: a case report and review of the literature. J Pediatr Hematol Oncol. 2006; 28: 115–119.
Kardous G, Baumann I, Passmore SJ, et al. Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7. Blood. 2003;102:1997-2003.
Gohring G, Michalova K, BeverlooHB, et al. Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome. Blood. 2010;116:3766-3769.
Boultwood J, Lewis S, Wainscoat JS. The 5q- syndrome. Blood. 1994; 84:3253-3260.
Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009 May 28;360:2289-2301.
Verburgh E, Achten R, Louw VJ, et al. A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification. Leukemia. 2007;21:668–677.
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
Tel: (001)347-983-5186